Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YN001 and Rosuvastatin PK and Safety in Healthy Volunteers
NCT07309042Phase 1Completed
- Sponsor
- Beijing Inno Medicine Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of YN001 in atherosclerotic cardiovascular disease (ASCVD) and cerebrovascular disease (3 arms), sponsored by Beijing Inno Medicine Co., Ltd. Primary endpoint: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) at 84 days. Started Dec 2025; status: completed.
02
Drugs
YN001
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)cerebrovascular disease
Beyond the preview
Go deeper on NCT07309042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07309042.